CLAIMS

1. A nucleic acid molecule comprising:

(i) a promoter,

(ii) an AAV *cap* gene, and

(iii) an AAV *rep* gene,

in the above 5' → 3' order, wherein the *cap* gene and the *rep* gene are both operably-associated with the promoter, and wherein the *rep* gene is also operably-associated with an IRES.

2. A nucleic acid molecule as claimed in claim 1, wherein:

(a) the *rep* gene encodes Rep78, Rep68, Rep52 and Rep40; or

(b) the *rep* gene only encodes one, two or three of Rep78, Rep68, Rep52 and Rep40.

3. A nucleic acid molecule as claimed in claim 1, wherein the *rep* gene:

(a) encodes Rep78 and Rep52, but does not encode Rep68 or Rep40;

(b) encodes Rep68 and Rep40, but does not encode Rep78 or Rep52;

(c) encodes Rep68 and Rep52, but does not encode Rep78 or Rep40; or

(d) encodes Rep78 and Rep40, but does not encode Rep68 or Rep52.

4. A nucleic acid molecule as claimed in any one of the preceding claims, wherein Rep52 and/or Rep40 are not transcribed from the said promoter.

5. A nucleic acid molecule as claimed in claim 4, wherein Rep52 and/or Rep40 are transcribed from a p19 promoter.

6. A nucleic acid molecule as claimed in any one of the preceding claims, wherein the nucleotide sequences of the *rep* and *cap* genes are AAV serotype 2 *rep* or *cap* genes.

7. A nucleic acid molecule as claimed in any one of the preceding claims, wherein the promoter is a cytomegalovirus immediate early (CMV) promoter.

8. A nucleic acid molecule as claimed in any one of claims 1 to 6, wherein the promoter is an inducible promoter.

9. A nucleic acid molecule as claimed in any one of the preceding claims, wherein the IRES is a Picornavirus IRES (Encephalomyocarditis virus, EMCV IRES) or an Aphthovirus IRES (Foot-and-mouth disease virus, FMDV IRES).

10. A RNA molecule comprising:

(i) an AAV *cap* gene, and

(ii) an AAV *rep* gene,

in the above 5' → 3' order, wherein the *rep* gene is operably-associated with an IRES.

11. A plasmid or vector comprising a nucleic acid molecule as defined in any one of claims 1 to 9.

12. A kit comprising

(a) a plasmid or vector as claimed in claim 11, together with one or both of:

(b) an AAV Transfer Plasmid comprising a transgene flanked by ITRs;

(c) a Helper Plasmid comprising one or more genes selected from E1A, E1B, E2A, E4 and VA.

13. A kit as claimed in claim 12, wherein the Helper Plasmid does not comprise an E2A gene.

14. A kit comprising

(a) a plasmid or vector as defined in claim 11, together with one or both of the following:

(b) an AAV Transfer Plasmid comprising a transgene flanked by ITRs;

(c) a mammalian host cell, preferably HEK293, comprising one or more viral genes selected from E1A, E1B, E2A, E4 and VA expressible from the host cell genome.

15. A kit as claimed in claim 14, wherein the mammalian host cell does not comprise an E2A gene expressible from the host cell genome.

16. A mammalian cell comprising a nucleic acid molecule, plasmid or vector as claimed in any one of claims 1 to 9 or 11, preferably wherein the mammalian cell is a human cell, more preferably a HEK293 cell or a derivative thereof.

17. Use of a mammalian cell as claimed in claim 16 in the production of an AAV particle.

18. A process for producing an AAV packaging cell, the process comprising the steps:

(a) stably integrating a nucleic acid molecule as claimed in any one of claims 1 to 9 or a plasmid or vector as claimed in claim 11 into a mammalian cell,

thereby producing a mammalian cell that expresses AAV *rep* and *cap* genes.

19. A process for producing AAVs, the process comprising the steps:

(a) introducing a Transfer Plasmid comprising 5'- and 3'-AAV ITRs flanking a transgene into an AAV packaging cell, the AAV packaging cell comprising a nucleic acid molecule as claimed in any one of claims 1 to 9 and sufficient helper genes, preferably selected from one or more of E1A, E1B, E2A, E4 and VA, for packaging the Transfer Plasmid, the helper genes either being present in an episomal Helper Plasmid within the cell or being integrated into the packaging cell genome;

(b) culturing the cell under conditions such that AAVs are assembled and secreted by the cell; and

(c) harvesting packaged AAVs from the supernatant, and optionally purifying the harvested AAVs.

20. A process as claimed in claim 19, wherein the helper genes do not include an E2A gene.

21. A process as claimed in claim 19 or claim 20, wherein the transgene encodes a CRISPR enzyme, preferably Cas9 or Cpf1, or a CRISPR sgRNA.